Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
The National Institute for Health and Care Excellence (NICE) has approved the use of PD-1 agonist nivolumab with anti-CTLA-4 ipilimumab to treat melanoma patients in the UK through the NHS.
The announcement follows the publication of updated results of the phase III CheckMate 067 trial at ASCO 2016, with a median progression free survival (PFS) of 11.5 months for the combination, compared to 6.9 months for nivolumab and 2.9 months for ipilimumab as single agents.
The combination has already met FDA approval in America for the treatment of melanoma.
Nivolumab has previously been recommended as a single agent by NICE and The German Institute for Quality and Efficiency in Health Care (IQWiG) to treat melanoma, and is the subject of significant interest to treat many tumour types.
Ipilimumab is similarly in demand, in combination with other immunotherapies, alongside radiotherapy or as a single agent to treat metastatic melanoma.
Bristol Myers-Squibb, who produce both drugs, have also recently announced investigations into their efficacy in treating lung cancer.
Source: NICE
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.